Anchiano is a biopharmaceutical company that specializes in the development of Targeted Cancer Therapies for the treatment of numerous types of cancer. The Company's technology offers a safe and long-term treatment of cancer, with no adverse effects. BioCancell was co-founded in 2004 by Professor Avraham Hochberg, Professor of Molecular Biology at the Hebrew University of Jerusalem, based on technology developed by him over the past 25 years. The drug candidates developed by the Company are targeted and their goal is to selectively destroy the cancer cells without affecting healthy cells (‘Targeted Cancer Therapy'). The approach is based on the identification of target genes, such as H19, that are expressed only in cancerous tumors, and not in healthy cells, and on the use of those genes' regulatory sequences for the activation of a toxin inside the cancerous cells only, thus destroying them without harming healthy cells. BioCancell's leading drug candidate, BC-819, has completed a Phase IIb clinical trial for the treatment of bladder cancer, as well as additional clinical trials for other cancer indications. BioCancell’s Phase I clinical trial for BC-821, scheduled to commence in 2015, is a continuation of the success of pre-clinical studies that have examined the use of BC-821 as a treatment for several cancer indications
Sector:
Health Technology
Industry:
Biotechnology
Employees:
12
Frequently Asked Questions
What is Market Cap of Chemomab Therapeutics Ltd - ADR?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Chemomab Therapeutics Ltd - ADR market cap is $15.65M.
What is the 52-week high for Chemomab Therapeutics Ltd - ADR?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Chemomab Therapeutics Ltd - ADR 52 week high is $3.58 as of September 26, 2026.
What is the 52-week low for Chemomab Therapeutics Ltd - ADR?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Chemomab Therapeutics Ltd - ADR 52 week low is $1.35 as of September 26, 2026.
What is Chemomab Therapeutics Ltd - ADR stock price today?
Chemomab Therapeutics Ltd - ADR stock price today is $2.16.
What was Chemomab Therapeutics Ltd - ADR stock price yesterday?
Chemomab Therapeutics Ltd - ADR stock price yesterday was $2.20.
What is the PE ratio of Chemomab Therapeutics Ltd - ADR?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Chemomab Therapeutics Ltd - ADR's P/E ratio is -2.12.
What is the Price-to-Book ratio of Chemomab Therapeutics Ltd - ADR?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Chemomab Therapeutics Ltd - ADR P/B ratio is 1.802.
What is the 50-day moving average of Chemomab Therapeutics Ltd - ADR?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Chemomab Therapeutics Ltd - ADR 50-day moving average is $2.12.
How many employees does Chemomab Therapeutics Ltd - ADR have?